Recruiting Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial) NCT06859684 Conditions Adenocarcinoma, Carcinoma, Cholangiocarcinoma, +7 more Locations West China Hospital, Sichuan University — Chengdu, Sichuan, China View Trial Details
Recruiting Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC NCT06999694 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more Locations Chang Gung Memorial Hospital at Linkou — Taoyuan City, Taiwan View Trial Details
Recruiting Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC NCT06999707 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more Locations Chang Gung Memorial Hospital at Linkou — Taoyuan City, Taiwan View Trial Details
Enrolling by Invitation Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals NCT07088081 Conditions Adenocarcinoma, Atezolizumab and Bevacizumab in Hepatocellular Carcinoma, Carcinoma, +14 more Locations Ain Shams University — Cairo, Abbasya, Egypt View Trial Details
Active, Not Recruiting Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC NCT05092412 Conditions Bronchial Neoplasms, Carcinoma, Bronchogenic, Durvalumab, +10 more Locations Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China Henan Provincial People's Hospital — Zhengzhou, Henan, China West China Hospital Sichuan University — Chengdu, Sichuan, China View Trial Details
